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Dual Roles of Diadenosine Polyphosphates in Corneal
Epithelial Cell Migration
Ara´nzazu Mediero,1 Assumpta Peral,2 and Jesu´s Pintor1
PURPOSE. To investigate the influence of diadenosine polypho-
sphates on the rate of corneal epithelial cell migration.
METHODS. Primary corneal epithelial cell cultures were ob-
tained from New Zealand White rabbits. Immunocytochemical
experiments were performed by fixing the cells with 4% para-
formaldehyde (PFA) and incubated with cytokeratin 3 primary
antibody, which was subsequently incubated with a secondary
IgG mouse labeled with FITC, and the cells were observed
under confocal microscopy. Migration studies were performed
by taking confluent monolayers that were wounded with a
pipette tip and challenged with different di- and mononucle-
otides with or without P2 antagonist (n  8 each treatment).
For concentration–response analysis, compounds were tested
in doses ranging from 108 to 103 M (n  8). The stability of
the dinucleotides was assayed by HPLC, with an isocratic
method (n  4).
RESULTS. Cells under study were verified as corneal epithelial
cells via the immunocytochemical analysis. Cell migration ex-
periments showed that Ap4A, UTP, and ATP accelerated the
rate of healing (5, 2.75, and 3 hours, respectively; P  0.05;
P  0.001), whereas Ap3A, Ap5A, and UDP delayed it (6.5, 10,
and 2 hours, respectively; P  0.05). ADP did not modify the
rate of migration. Antagonists demonstrated that Ap4A and
Ap3A did activate different P2Y receptors mediating corneal
wound-healing acceleration and delay. Concerning the possi-
ble degradation of the dinucleotides, it was almost impossible
to detect any products resulting from their cleavage.
CONCLUSIONS. Based on the pharmacological profile of all the
compounds tested, the two main P2Y receptors that exist in
these corneal cells are a P2Y2 receptor accelerating the rate of
healing and a P2Y6 receptor that delays this process. (Invest
Ophthalmol Vis Sci. 2006;47:4500–4506) DOI:10.1167/
iovs.06-0209
There are certain physiological processes that are naturallymodified by the action of extracellular nucleotides, such as
ATP or UTP.1 These nucleotides alter the functioning of cells
and tissues because they can bind to membrane receptors
termed P2 purinoceptors.2 Two main families of P2 receptors
have been studied: metabotropic P2Y and ionotropic P2X
receptors. P2Y receptors are seven transmembrane domain
proteins coupled to G proteins that trigger different signal-
transduction mechanisms. Eight different proteins have been
cloned so far: P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13,
and P2Y14
3. Although in general all the receptors are widely
distributed, the last four are particularly important in processes
such as the maintenance of the vascular tone and platelet
aggregation.4,5
On the other hand, P2X ionotropic receptors are formed by
two or three different subunits to construct an active recep-
tor.6 It seems that in native tissues P2X receptors are formed by
a heteromeric combination of subunits rather than a homo-
meric one.7 P2X receptors are involved in processes in which
cells are excited by the action of nucleotides, a mechanism that
is extraordinarily important in excitable cells such as neurons.8
The eye presents both types of P2 receptors in most of its
structures.9 Although in some cases it is not clear which P2
receptor subtype is activated by the nucleotides, the use of cell
cultures obtained from different areas in combination with the
development of P2 receptor antibodies provides an accurate
picture of the different nucleotide receptors present in the eye.
In eye sections, by using P2Y receptor antibodies, it has been
possible to see the existence of those receptors in the cornea,
iris, ciliary processes, and retina, among other areas.10
It is generally accepted that the main naturally active nucle-
otide is ATP, but over the past 20 years, a new group of
extracellular nucleotides, the dinucleoside polyphosphates,
have received a great deal of attention.11 Constituted by two
nucleosides linked by a variable number of phosphates (from
two to seven) and mostly formed with two adenosine moieties
(diadenosine polyphosphates), they can activate P2 nucleotide
receptors as well as their own dinucleotide receptors.12 Dia-
denosine polyphosphates have been described in tears and in
the aqueous humor, together with other adenine mononucle-
otides. In this sense, and acting within the eye, it has been
possible to demonstrate the action of diadenosine polyphos-
phates regulating IOP. This effect seems to occur in the tra-
becular meshwork cells where P2Y1 receptors reduce IOP
when eyes are challenged with diadenosine tetraphosphate
(Ap4A).
13
On the ocular surface the presence of diadenosine polypho-
sphates, mainly diadenosine triphosphate, Ap3A; diadenosine
tetraphosphate, Ap4A; and diadenosine pentaphosphate, Ap5A,
have been described.14,15 These compounds are able to in-
crease tear production in rabbits by a mechanism in which P2Y
receptors are involved. More recently, Ap4A and UTP have
been observed as active substances facilitating the rate of
corneal re-epithelialization in New Zealand White rabbits.16
Although the results are clear, the limitation of the animal
model does not allow full investigation of the role of diade-
nosine polyphosphates on corneal wound healing. For this
reason, in the present experimental work, we have optimized
a primary corneal epithelial cell culture, and we have investi-
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ments were performed in accordance with the European Communities
Council Directive (89/609/EEC). Primary corneal epithelial cells were
obtained from healthy eyes from adult New Zealand White rabbits
euthanatized with pentothal sodium. Cell culture was performed ac-
cording to the protocol described by Gipson and Grill,17 with some
minor modifications. Briefly, eyes were enucleated, and the globes
were placed in Hanks’ balanced salt solution (HBSS) while corneal
dissection under a dissecting microscope was performed. The cornea
was removed along the limbus and cut into pieces. Incubation of the
corneas in 1.0 U Dispase II (Roche Molecular Biochemicals, Indianap-
olis, IN) was performed for 1 hour at 37°C in 5% CO2 and 95%
humidity. The epithelium was peeled from the stroma and placed in
0.05% trypsin 0.5 M EDTA for 20 minutes at 37°C. The epithelium was
collected in a tube containing 10 mL Dulbecco’s modified medium
(DMEM; Invitrogen, Paisley, UK) supplemented with 10% FBS and 1%
penicillin-streptomycin (both from Invitrogen), and centrifuged twice
at 1100 rpm for 6 minutes at 4°C. Finally, cells were resuspended in
DMEM supplemented with 10% FBS and 1% penicillin-streptomycin
and cultured in six multiwell plates until confluence. Cells were kept
in a CO2 incubator at 37°C, 5% CO2, and 95% humidity until conflu-
ence.
Immunocytochemistry for Cytokeratin 3
Corneal epithelial cells were grown to 80% confluence on coverslips.
After three washes with 10 phosphate-buffered saline (PBS), the cells
were fixed for 15 minutes at room temperature with 4% paraformal-
dehyde in 0.15 M PBS. Washed again with PBS 10, the cells were
permeabilized with blocking solution (PBS 1 BSA 3% Triton X-100
FBS 5%) for 1 hour at 37°C, to block the nonspecific binding sites. Cells
were then washed with PBS 1 BSA 3% and incubated with primary
mouse monoclonal anti-cytokeratin 3 (1:100, Biogenesis, Du¨sseldorf,
Germany) or PBS 1 BSA 3% for negative controls overnight at 4°C.
Cells were washed twice in PBS 1 BSA 3% and incubated with the
secondary antibody goat anti IgG mouse FITC (1:200; Sigma-Aldrich, St.
Louis, MO) for 1 hour at 37°C. Finally, coverslips were applied to the
slides with mounting medium (Invitrogen). The cells were observed by
confocal microscope (Axiovert 200M; Carl Zeiss Meditec GmbH, Jena,
Germany), equipped with a Pascal confocal module (LSM 5; Zeiss). All
images were managed with the accompanying Pascal software.
Migration Assays
To study the effect of dinucleoside polyphosphates and mononucle-
otides on corneal epithelial migration (as occurs in vivo in wound
healing), experiments were performed on confluent monolayers on
24-well plates. Confluent monolayers were wounded by scraping the
cell monolayer with a pipette tip, with just one touch of the monolayer
and without any further movement.18,19 The initial wound size and
shape were comparable (60,000–80,000 m2), to account for the
variations in wound closure due to size, so that healing showed the
same mechanistic features as previously indicated by other investiga-
tors.20 Wound area measurements (for each treatment) were collected
from eight different wells and averaged as one measurement (mean 
SEM). These eight experiments were performed in four independent
primary rabbit corneal epithelial cell cultures.
Dinucleoside polyphosphates (Ap3A, Ap4A, Ap5A) and nucleotides
(ATP, UTP, ADP, UDP) were assayed across a wide range of doses, from
0.01 M to 1 mM, to obtain the corresponding concentration–re-
sponse curves. Some wounds were used as the control (treated with
Locke medium), and others were treated with dinucleotides and nu-
cleotides (n  8 each). After the culture medium was removed, cells
were challenged for 2 minutes with the dinucleotide or nucleotide in
Locke medium, to avoid interference, as previously reported for media
such as DMEM.21 After this incubation, cells were washed, and fresh
DMEM was added. The nucleotide dose was added to the wound at
time 0 and every 6 hours, as previously described for rabbits.16 Images
were captured every 2 hours during the first 10 hours and at 24 hours
after the beginning of the experiment. Wounds were measured using
the confocal microscope (LSM 5 Pascal software and Axiovert 200 M;
Carl Zeiss Meditec, GmbH).
To compare the effect of the tested compounds in wound healing,
we assayed them at a single dose of 100 M, where the eight com-
pounds reached their maximum effect. To perform these experiments
we followed the same protocol as that described for concentration–
response curve assays (n  8 each).
P2 receptor antagonists such as pyridoxalphosphate-6-azophenyl-
24disulfonic acid (PPADS), suramin (both from Tocris, Bristol, UK)
and reactive blue 2 (RB2; Sigma-Aldrich) were initially assayed at 100
M in the presence and absence of the agonist (Ap3A or Ap4A, 100 M
each). Antagonist (100 M) in Locke medium was exposed to
wounded cells 30 minutes before the application of 100 M Ap3A or
Ap4A (together with the antagonist) in Locke medium, by using the
same procedure as described earlier (n  8).
Graded doses of suramin or RB2 ranging from 0.1 M to 1 mMwere
assayed to obtain concentration–response curves in the presence of
Ap4A 100 M (for Suramin) or Ap3A 100 M (for RB2; n  8 each).
Analysis of Data
To model the nonlinear decrease in wound area during epithelial
healing, the constant-velocity method previously described20 was used
with some modifications. Briefly, migration rates were determined by
linear regression of the decrease in wound area during 10 hours of
measurements and were obtained by the slope of the regression line,
expressed as  area decrease per hour. The total time of wound
closure was calculated by extrapolation of the best fit of the regression
line during the healing phase to 100% closure of each wound tested.
Migration rates, expressed as estimated migration rates (EMR) and
the estimated time for wound closure, presented as estimated healing
time (EHT) in treated and control wounds were compared using
one-way ANOVA. Average values were expressed as mean  SEM. The
levels of significance for the differences are indicated in each case in
the figure legends.
When we represent the linear regression of the decrease in wound
area, data are expressed as a percentage of the time-0 wound width, to
normalize variability in wounding from well to well and experiment to
experiment, according to a strategy described by others.19,22 EMR
variations are expressed as % area decrease  hours1, and all data are
related to the control to minimize the intrinsic levels in the medium.
Analysis of the Dinucleotides by HPLC
Determination and quantification of the diadenosine polyphosphate’s
stability after the assays were performed by HPLC. The chromato-
graphic system consisted of an isocratic HPLC pump (1515; Waters,
Milford, MA), a dual-absorbance detector (2487; Waters), and an injec-
tor (Reodyne, Rohnert Park, CA), all managed by HPLC system soft-
ware (Breeze; Waters). The column was a C18 (15 cm length, 0.4 cm
diameter; Novapack) from Waters.
The system was equilibrated overnight with the following mobile
phase: 0.1 M KH2PO4, 2 mM tetrabutyl ammonium, 17% acetonitrile
(pH 7.5). Dinucleotides were detected at 260-nm wavelength. Peaks
were transformed into concentrations by means of external standards
of known concentrations of diadenosine polyphosphates.
RESULTS
Immunocytochemistry for Cytokeratin 3
To verify that the isolated cells were corneal epithelial cells, an
immunocytochemical analysis with cytokeratin 3 was per-
formed. This protein is a component of intermediate filaments
in epithelial cells and is a specific marker for corneal epithelial
cells.23 Corneal epithelial cells in culture depict a polygonal
morphology when observed under Nomarsky optics. Com-
bined with the specific marker cytokeratin 3, it was possible to
confirm that all the cells obtained after the primary culture
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were positive for this protein (data not shown). Labeling was
present across the whole cytoplasm, according to the position
of intermediate filaments in the cell. Thus, we can conclude
that the isolated cells were corneal epithelial cells, and so we
investigated the role of extracellular dinucleotides in these
cells.
Concentration–Response Curves for the Effects of
Di- and Mononucleotides on Migration Rate
To know whether dinucleoside polyphosphates (Ap3A, Ap4A,
and Ap5A) and mononucleotides (ATP, UTP, ADP, and UDP)
could change the cell migration rate, we assayed them over a
wide range of concentrations (0.01 M to 1 mM), to generate
concentration–response curves.
When the seven compounds were tested, three different
effects on the rate of migration and healing time were found.
Some of the tested dinucleotides and nucleotides (Ap4A, ATP,
and UTP) increased the wound-healing rate, others (Ap3A,
Ap5A, and UDP) reduced cell migration, and ADP did not alter
cell migration when compared with the controls (data not
shown).
In Figure 1A the EMR concentration–response curves for
those compounds increasing cell migration—Ap4A, ATP, and
UTP—is presented. Graded doses of both Ap4A and UTP elic-
ited a sigmoid response pattern that had a pD2 value of 6.05 
0.49 and 5.97  0.6, respectively (EC50 of 0.89 M for Ap4A
and 1.07 M for UTP). Unexpectedly, when the concentra-
tion–response curve for ATP was studied, it was found that this
mononucleotide followed a bell-shaped curve (Fig. 1A). Expo-
sure to low agonist concentrations (1 M) was associated with
the highest mobility (pD2 of 6), whereas higher concentrations
(10 M and 1 mM) failed to induce cell migration. It was only
the single dose of 1 M that had an effect in increasing wound
healing.
When the same experiments were performed for those
compounds reducing the rate of migration (Ap3A, Ap5A, and
UDP), it was possible to observe sigmoid concentration–re-
sponse curves. The pD2 obtained was 5.29  1.5 for Ap3A,
5.759  0.09 for Ap5A, and 5.62  0.97 for UDP, resulting in
an EC50 of 5.13, 1.73, and 2.39 M, respectively (Fig. 1B).
Based on the concentration–response curves, it was possi-
ble to display a rank order of potency for those compounds
increasing the rate of migration, which was Ap4A  UTP 
ATP. In the same way, the order of potency of those com-
pounds that reduce the rate of healing was Ap5A  Ap3A 
UDP. These pharmacology profiles suggest the existence of
two purinergic receptors: a P2Y2-involved cell migration and a
P2Y6-decreasing cell migration.
Since one of the most relevant features of the tested nucle-
otides is their ability to accelerate or delay wound healing, we
compared the ability of all by assaying them at the concentra-
tion that produced the maximum effect (100 M).
In Figure 2A, a series of micrographs, in which we can
compare the migration process after treatment with Ap4A (100
M) compared with the control, is presented. As is shown,
after the challenge with Ap4A 100 M, the migration rate
increased, and the time necessary to close the wound was
significantly reduced. This can also be observed in Figure 2B,
where a plot for Ap4A 100 M showing variation of the
wounded area versus time is presented. Ap4A significantly
increased the EMR relative to control, accompanied with a
decrease in EHT.
In Table 1, the results for the whole series of tested com-
pounds (all at 100 M) in terms of EMR and EHT are presented.
Among the tested compounds, Ap4A showed an increase in
EMR with a decrease in EHT (P  0.001). The same behavior
occurred with ATP and UTP (P  0.05), which also increased
EMR and reduced EHT. In contrast, the EMR for Ap3A was
reduced, whereas the EHT was increased. The same behavior
was obtained with Ap5A (P  0.05). Finally, ADP presented an
EMR and EHT similar to the control values.
Studies with P2 Receptor Antagonists
To understand fully the receptors involved in the two pro-
cesses described in the present manuscript, the P2 antagonists
suramin, PPADS, and RB2 were assayed at a single dose of 100
M in the presence of Ap4A and Ap3A (both at 100 M).
Wounded cells were preincubated for 30 minutes in the pres-
ence of the indicated antagonist and then were incubated for 2
minutes with the corresponding agonist.
As shown in Table 2, the application of a single dose of 100
M of suramin, PPADS, or RB2 significantly reversed the effect
of Ap4A, because the EMR was reduced while the EHT was
concomitantly increased. For the effect of Ap4A, the most
effective antagonist reducing the rate of healing was suramin
(P  0.05).
When the antagonists were tested with Ap3A, suramin did
not revert the delayed effect in the rate of healing triggered by
FIGURE 1. Concentration–response curves for di- and mononucleoti-
des on the rate of migration. (A) The concentration–response curves
for the three compounds that increased migration rate (Ap4A, ATP, and
UTP). Ap4A and UTP follow a sigmoid response pattern, whereas ATP
follows a bell-shaped curve. (B) Concentration–response curves for the
compounds delaying the rate of migration (Ap3A, Ap5A, and UDP).
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this dinucleotide (Table 3). Unexpectedly, the application of
PPADS and RB2 potentiated the effect of Ap3A, leading to a
lower EMR. Thus, these results indicate that PPADS and RB2
may favor the action of Ap3A over the receptor that inhibits the
cell migration rate (P  0.05).
The ability of suramin to antagonize the effect of Ap4A was
tested at a wide range of concentrations of the antagonist.
Figure 3A shows that graded concentrations of suramin de-
creased the ability of Ap4A to accelerate the rate of healing.
The pA2 for suramin was 5.17  0.59 (IC50 of 6.76 M). When
the same experiment was performed with Ap3A and RB2 (Fig.
FIGURE 2. Effects of Ap4A on cor-
neal epithelial cell migration. (A)
Shows a series of pictures to com-
pare the migration process in control
conditions and after 100 M Ap4A,
on cultured cell monolayers. The mi-
crographs were obtained at 0, 6, and
10 hours in the absence (control)
and in the presence of Ap4A 100 M.
(B) Plot representing the variation of
the wounded area versus time. Ap4A
100 M increased EMR and reduced
EHT when compared with the con-
trol.








Control 4.20  0.15 0
Ap3A 3.83  0.18 	6.5
Ap4A 6.25  0.33*** 5
Ap5A 3.14  0.11* 	10
ATP 4.56  0.09 3
UTP 5.07  0.28* 2.75
ADP 4.19  0.18 0
UDP 3.82  0.35 	2
Data are the mean  SEM of eight independent experiments (n 
24 for control and n  8 for each treatment). EMR is calculated as %
reduction  hour1. For EHT, 	 is a delay over the control, and  is
an acceleration over the control.
* P  0.05, *** P  0.001 versus control.








Control 4.20  0.15 0
Ap4A 6.25  0.33*** 5
Suramin 	 Ap4A 3.06  0.34* 	11
PPADS 	 Ap4A 3.75  0.19 	6
RB2 	 Ap4A 3.63  0.33 	7
Data are as described in Table 1.
* P  0.05, *** P  0.001 versus control.
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3B), the antagonist presented a pA2 of 3.48  0.30 (IC50 of
331.13 M).
When the three antagonists were assayed in the absence of
any agonist, all reduced the rate of re-epithelialization, the best
being PPADS (results not shown). This effect indicates the
presence of extracellular nucleotides in the medium and that
these nucleotides may activate preferentially the receptor that
accelerates re-epithelialization (P2Y2). A possible explanation
of this may be the presence of nucleotides at the extracellular
medium as a consequence of the mechanical stress. Lazarowski
et al.24 have demonstrated that, even in the most controlled
conditions, epithelial cells can release nucleotides when, for
example, cells are simply superfused with buffer. It could be
the case that minor but slightly effective extracellular concen-
trations of nucleotides may be present after the application of
the different agonists and antagonists. This “background” nu-
cleotide concentration would be specially detected when an-
tagonists are present in the medium.
Stability of Diadenosine Polyphosphates
Dinucleotides can be cleaved by the action of ectoenzymes
which transform these molecules into mononucleotides. It
could be the case that the effects reported herein are due to
the degradation products of the dinucleotides rather than to
their own effects. To prove this, both Ap4A and Ap3A were
assayed under the conditions described in the Methods sec-
tion.
Concerning the extracellular behavior of Ap4A, we did not
observe any product derived from its hydrolysis after 2
minutes of incubation (Figs. 4A, 4C). Even in the presence of
the antagonist suramin (which has been reported to block
some ectonucleotidases), it was not possible to see any
difference at all.
When Ap3A was used instead, no hydrolysis was observed
after 2 minutes (Figs. 4B, 4C). Also, in the presence of the
antagonist RB-2, the lack of hydrolysis was observed.
DISCUSSION
Diadenosine polyphosphates are active molecules present in
tears that can exert several effects on corneal epithelium.
When applied on corneal epithelial cells in culture, diade-
nosine polyphosphates elicit different effects, depending on
the phosphate chain bridging between the two adenosines.
Ap4A accelerated the rate of re-epithelialization whereas Ap3A
or Ap5A did the opposite, delaying the wound-healing process.
Other nucleotides, such as ADP did not modify the rate of
healing when compared with the control. In both cases, a
positive or negative effect on re-epithelialization, the effects
may be justified by the activation of different P2Y receptors
subtypes, according to our pharmacological studies. It is clear
that the pharmacology of P2 receptors is rather complicated
due to the lack of selective antagonists. A possible picture of
the receptors involved in the acceleration of re-epithelializa-
tion or its delay may be obtainable by studying the behavior of
several purinergic agonists.
The increase in the rate of re-epithelialization has been
observed when Ap4A, UTP, and ATP were applied. This profile
matches quite well with that described by Lazarowski et al.,25
in which Ap4A and UTP are the best agonists on the cloned
P2Y2 receptor. A similar P2Y2 profile has been previously
described for corneal wound healing and tear secretion, but
the limitations of using living animals did not permit us to
obtain conclusive results for those compounds that delay re-
epithelialization.16 With corneal epithelial cells in culture, it
was possible to detect some dinucleotides that clearly reduced
the rate of healing. Together with the study of mononucleo-
FIGURE 3. Concentration–response curves for the antagonists
suramin and RB-2. (A) Concentration–response curve for the antago-
nist effect of suramin in the presence of 100 M Ap4A. (B) Concen-
tration–response curve for the antagonist effect of RB-2 on 100 M
Ap3A.








Control 4.20  0.15 0
Ap3A 3.83  0.18 	6.5
Suramin 	 Ap3A 3.92  0.39 	6
PPADS 	 Ap3A 3.33  0.38 	10.5
RB2 	 Ap3A 3.06  0.38* 	12.5
Data are as described in Table 1.
* P  0.05 versus control.
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tides it was possible to obtain a profile of those nucleotides
that reduce the rate of re-epithelialization. A profile with the
rank order of Ap5A Ap3A UDP suggests the involvement of
a P2Y6 receptor. This fact alters the idea of the P2Y6 receptor’s
being a pyrimidinoceptor, sensitive to UTP and UDP. Never-
theless, studies performed with diadenosine polyphosphates
and P2Y6 receptors, heterologously expressed in 1321N1 cells,
demonstrate that both Ap3A and Ap5A are agonists of the P2Y6
receptor, although the concentration required for the receptor
stimulation are higher than those of the best agonist, UDP.26
Also, recently the design of novel dinucleoside polyphosphates
with uridine as the nucleoside moiety (UpnU) has demon-
strated that some of them are quite effective in activating the
P2Y6 receptor.
27
The involvement of metabotropic P2 receptors in corneal
wound healing has been reported by other groups.28–30 The
presence of P2Y2, P2Y4, and P2Y11, on corneal epithelial
cells seems to be clear from a pharmacological point of
view. Discussion arises when the presence of P2Y1 or P2Y6
is investigated. The assay of UDP, together with the enzyme
hexokinase suggests the presence of a P2Y6 receptor in
these cells.28
Concerning the second-messenger system underlying the
activation of those receptors, it seems that both intracellular
Ca2	 mobilization29–31 and MAP kinase cascade activation28
are involved. These intracellular mechanisms which accel-
erate the rate of healing, seems to be triggered by P2Y2 and
P2Y4 membrane receptors.
30 These results match well with
the effect of Ap4A, UTP, and ATP described in the present
work, which indicates the activation of a P2Y2 receptor.
Ap4A is effective inducing an increase in the rate of migra-
tion by stimulating a P2Y2 receptor, whereas Ap3A and Ap5A
do the opposite by activating a P2Y6 receptor. This dual role of
diadenosine polyphosphates may have a physiological meaning
in the intact tissue. Corneal wound healing is a process that
occurs in three main steps: lag phase, migration, and mito-
sis.31,32 It could be the case that in the intact corneal epithe-
lium, P2Y2 receptors would be the relevant ones facilitating
the migration rate (termed phase 2) in intact corneas. It is
necessary to take into consideration that in the model we use,
the lag phase (phase 1) is reduced. This reduction is because
the cells do not have to perform some of the pathophysiolog-
ical processes that occur in the intact cornea after injury. In the
whole cornea, polymorphonuclear leukocytes remove ne-
crotic cells from the wound margin. Also, hemidesmosomal
attachments between the basement membrane and the basal
cells disappear.31,32 All these phenomena did not occur in our
preparation, because it contained only a monolayer of epithe-
lial cells.
On the other hand, P2Y6 would be critical in stopping
migration and starting the third phase (mitosis). It is clear that
we do not have any evidence for the role of P2Y6 receptor to
confirm this idea, but it would not be strange to think that
P2Y2 and P2Y6 are switches that control the transition from
wound-healing phase 2 to phase 3. More experiments will be
necessary to confirm this hypothesis fully.
Preliminary experiments performed with living rabbits es-
tablished that the topical application of certain nucleotides
clearly reduce the time of corneal wound healing.16 At that
moment, we were not able to indicate whether the nucleotides
were activating epithelial cell P2Y receptors or if the topical
application of these substances were inducing tear secretion,
and a component present in the tears was the responsible for
the re-epithelialization. In the present work, it seems clear that
the application of Ap4A and other mononucleotides acts di-
rectly on the P2Y receptors present in the rabbit corneal
epithelial cells and that they are responsible for the wound-
healing effect.
Diadenosine polyphosphates are present in rabbit tears.15
They therefore, may contribute to the modification of the rate
of healing. Because the only two dinucleotides present in tears
are Ap4A and Ap5A and considering that the first accelerates
the rate of migration and the other produces just the opposite
effect, we may observe an apparent no-effect. Nevertheless, a
detailed study of the concentrations of both dinucleotides in
the rabbit tears indicates that Ap4A concentration is five times
higher than that of Ap5A (3 M for Ap4A and 0.6 M for Ap5A).
Taking these results together and according to our dose–r-
esponse curves, the predominant effect would be the one
triggered by Ap4A.
Another interesting question related to the previous one is
whether the levels of both compounds vary after corneal in-
jury. In vivo experiments performed in our laboratory demon-
strated that the levels of Ap4A and Ap5A are significantly re-
duced after the injury but they recover after 10 hours (results
not shown). Under the experimental conditions, although
Ap4A and Ap5A concentrations were reduced, they kept the
same proportion between the respective concentrations that
occur in normal tears (3 M Ap4A and 0.6 M Ap5A, a ratio pf
5:1). Furthermore, they remain low during the lag phase and
FIGURE 4. Stability of Ap3A and Ap4A on corneal epithelial cells in
culture. (A) Diadenosine triphosphate stability was assayed as de-
scribed in methods. Ap3A, either alone or in the presence of RB-2, was
only minimally degraded by the extracellular enzymes. (B) When the
same experiments were performed for Ap4A, but with suramin as
ectoenzyme inhibitor, minimal degradation was detected. (C) Column
plot presenting the changes in the amount of Ap3A and Ap4A under the
conditions described in (A) and (B).
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recover during the migration phase, suggesting their involve-
ment in the migration process. Further experiments are
needed to see whether their levels and even their proportions
change in the mitosis phase.
In summary, diadenosine polyphosphates have a dual role
in corneal epithelial cells. On the one hand, Ap4A can acceler-
ate the rate of migration, whereas on the contrary, Ap3A and
Ap5A delay this process, probably starting others that remain
unknown. More work is necessary to understand fully the
cross-talk between these two actions and under what condi-
tions one is superimposed on the other.
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